Patients with end-stage kidney disease on dialysis (ESKD-D) have considerably worse transcatheter aortic valve replacement (TAVR) outcomes than patients with chronic kidney disease (CKD), according to new research out of the Cleveland Clinic.
The findings were published in the American Journal of Cardiology.
For the study, researchers tracked the outcomes of more than 42,000 CKD patients who underwent TAVR from January 2012 to December 2017. Data came from the National Readmissions Database (NRD). More than 6,000 patients included in the analysis had ESKD-D. The median age was 83 years old for CKD patients and 75 years old for ESKD-D patients. The median length of stay was four days for CKD patients and six days for ESKD-D patients.
Overall, lead author Abdelrahman I. Abushouk, MD, and colleagues found that patients with ESK-D who underwent TAVR experienced higher rates of in-hospital mortality, in-hospital acute myocardial infarction and in-hospital sepsis. These patients were also more likely to require blood transfusion or a permanent pacemaker.
The risk of in-hospital stroke and discharge with disability, on the other hand, was the same between the two groups.
The authors urged researchers looking at this topic in the future to focus on the development of “optimal risk stratification and outcome improvement strategies” for CKD patients undergoing TAVR.
Read the full analysis here.
Michael has more than 16 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.